Significant risk and associated factors of active tuberculosis infection in Korean patients with inflammatory bowel disease using anti-TNF agents
Adult
Male
Anti-Inflammatory Agents
610
Opportunistic Infections
Tertiary Care Centers
Immunocompromised Host
03 medical and health sciences
0302 clinical medicine
Crohn Disease
Risk Factors
616
Republic of Korea
Humans
Tuberculosis
Retrospective Studies
Tumor Necrosis Factor-alpha
Incidence
Adalimumab
Middle Aged
Infliximab
3. Good health
Treatment Outcome
Colitis, Ulcerative
Female
DOI:
10.3748/wjg.v21.i11.3308
Publication Date:
2017-09-17T23:09:13Z
AUTHORS (19)
ABSTRACT
AIM:To evaluate the incidence and risk factors of Korean tuberculosis (TB) infection in patients with inflammatory bowel disease (IBD) undergoing anti-TNF treatment. METHODS:The data IBD treated anti-TNFs 13 tertiary referral hospitals located southeastern region Korea were collected retrospectively.They failed to show response or intolerant conventional treatments, including steroids immunomodulators.Screening measures for latent TB (LTBI) Retrospective Study ORIGINAL ARTICLEactive after treatment identified. RESULTS:Overall, 376 agents recruited (male 255, mean age therapy 32.5 ± 13.0 years); 277 had Crohn's disease, 99 ulcerative colitis, 294 used infliximab, 82 adalimumab.Before treatment, screening tests LTBI an interferon gamma release assay a tuberculin skin test performed 82.2% patients.Thirty (8%) LTBI.Sixteen cases active one TB-related mortality occurred during 801 personyears (PY) follow-up (1997.4cases per 100000 PY) treatment.LTBI (OR = 5.76, 95%CI:1.57-21.20,P 0.008) WBC count < 5000 mm 3 4.5, 95%CI: 1.51-13.44,P 0.007) identified as independently associated factors. CONCLUSION:Anti-TNFs significantly increase IBD.The considerable burden marked immunosuppression might be attributed this risk.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (38)
CITATIONS (34)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....